BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9407961)

  • 21. Radiation-induced changes in skin type I and III collagen synthesis during and after conventionally fractionated radiotherapy.
    Keskikuru R; Jukkola A; Nuutinen J; Kataja V; Risteli J; Autio P; Lahtinen T
    Radiother Oncol; 2004 Mar; 70(3):243-8. PubMed ID: 15064008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The concentration of C-terminal propeptide of type I procollagen in blood serum in the course of mandibular fracture healing (preliminary report).
    Borys J; Grabowska SZ; Antonowicz B; Dryl D; Citko A; Rogowski F
    Rocz Akad Med Bialymst; 2001; 46():251-62. PubMed ID: 11780569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum levels of bone-specific alkaline phosphatase and procollagen type I carboxyterminal peptide in vitamin D deficiency.
    Nawawi H; Girgis SI
    Southeast Asian J Trop Med Public Health; 2002; 33 Suppl 2():124-30. PubMed ID: 12755282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases.
    Ebeling PR; Peterson JM; Riggs BL
    J Bone Miner Res; 1992 Nov; 7(11):1243-50. PubMed ID: 1466250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated preoperative serum ICTP is a prognostic factor for overall and disease-free survival in breast cancer.
    Keskikuru R; Bloigu R; Risteli J; Kataja V; Jukkola A
    Oncol Rep; 2002; 9(6):1323-7. PubMed ID: 12375042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum levels of procollagen type I carboxyterminal extension peptide in cancer patients with bone metastases.
    Santi I; Monti M; Viganò A; D'Aprile E; Rampoldi E; Castellani L; Accinni R; Cunietti E
    Int J Biol Markers; 1995; 10(2):107-12. PubMed ID: 7561234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of three serum assays for bone collagen formation during postmenopausal estrogen-progestin therapy.
    Suvanto-Luukkonen E; Risteli L; Sundström H; Penttinen J; Kauppila A; Risteli J
    Clin Chim Acta; 1997 Oct; 266(2):105-16. PubMed ID: 9437539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The aminoterminal propeptide of type I procollagen: evaluation of a commercial radioimmunoassay kit and values in healthy subjects.
    Tähtelä R; Turpeinen M; Sorva R; Karonen SL
    Clin Biochem; 1997 Feb; 30(1):35-40. PubMed ID: 9056107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum concentrations of the type I and III procollagen propeptides as biochemical markers of growth velocity in healthy infants and children and in children with growth disorders.
    Trivedi P; Risteli J; Risteli L; Hindmarsh PC; Brook CG; Mowat AP
    Pediatr Res; 1991 Sep; 30(3):276-80. PubMed ID: 1945568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases.
    Voorzanger-Rousselot N; Journe F; Doriath V; Body JJ; Garnero P
    Calcif Tissue Int; 2009 May; 84(5):348-54. PubMed ID: 19252761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is bone turnover a determinant of bone mass in rheumatoid arthritis?
    Cortet B; Flipo RM; Pigny P; Duquesnoy B; Boersma A; Marchandise X; Delcambre B
    J Rheumatol; 1998 Dec; 25(12):2339-44. PubMed ID: 9858427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma.
    Díaz-Martín MA; Traba ML; De La Piedra C; Guerrero R; Méndez-Dávila C; De La Peña EG
    Scand J Clin Lab Invest; 1999 Apr; 59(2):125-32. PubMed ID: 10353326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum markers of bone metabolism in dogs.
    Allen MJ; Hoffmann WE; Richardson DC; Breur GJ
    Am J Vet Res; 1998 Mar; 59(3):250-4. PubMed ID: 9522938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
    Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
    Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of serum hyaluronic acid and type I and III procollagen propeptides in extrahepatic biliary atresia.
    Trivedi P; Dhawan A; Risteli J; Risteli L; Mirza M; Cheeseman P; Mowat AP
    Pediatr Res; 1995 Oct; 38(4):568-73. PubMed ID: 8559611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma.
    Klepzig M; Jonas D; Oremek GM
    Anticancer Res; 2009 Feb; 29(2):671-3. PubMed ID: 19331219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Serum levels of carboxyterminal propeptide of type I procollagen (PICP), cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) and carboxyterminal parathyroid hormone-related protein (C-PTHrP) in hematological malignancies with bone lesions and hypercalcemia].
    Tanaka K; Shiraishi K; Sakamoto A; Jojima H; Masuchi K; Okubo Y; Tanaka M; Fuzimatsu Y; Fukahori S; Osabe S; Imamura Y; Honda J; Oizumi K
    Rinsho Ketsueki; 1998 Apr; 39(4):273-80. PubMed ID: 9597894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low synthesis rate of type I procollagen is normalized during active back rehabilitation.
    Hupli M; Hurri H; Luoto S; Risteli L; Vanharanta H; Risteli J
    Spine (Phila Pa 1976); 1997 Apr; 22(8):850-4. PubMed ID: 9127916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.